Nutritional composition and application thereof in improving and / or improving individual social behaviors

Abstract

The invention provides a nutritional composition and application thereof in improving and / or improving individual social behaviors. The composition comprises DHA (docosahexaenoic acid), ARA (arachidonic acid) and phospholipid, the phospholipid is sphingomyelin and / or lecithin, the mass ratio of DHA to phospholipid is (0.5-13): 1, and the mass ratio of ARA to phospholipid is (0.5-17): 1. The invention also provides a food containing the composition, and an application of the composition or the food in preparation of a product helpful for improving the social behavior of an individual.

Description

Technical Field

[0001] The present invention relates to the technical field of functional nutrient research, and in particular to a nutrient composition and application thereof that is helpful in enhancing and / or improving individual social behavior. Background Art

[0002] Social behavior refers to an individual's ability to interact with people around him or her and to take care of himself or herself. It is one of the attributes for assessing the developmental behavior level of children aged 0 to 6 years old (under 7 years old).

[0003] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0004] An object of the present invention is to provide a composition that helps to greatly enhance and / or improve the social behavior of an individual.

[0005] Another object of the present invention is to provide related applications of the composition.

[0006] The inventors of this case have discovered that polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA), and compositions further comprising sphingomyelin (SM) and / or lecithin (i.e., compositions comprising DHA, ARA, sphingomyelin and / or lecithin) can affect the social behavior of an individual. In particular, when DHA, ARA and sphingomyelin, especially milk phospholipids (milk SM), are combined in a certain proportion, they have a synergistic effect on enhancing and / or improving the social behavior of an individual.

[0007] On the one hand, the present invention provides a nutritional composition, which includes DHA, ARA, and phospholipids, wherein the phospholipids are sphingomyelin and / or lecithin, wherein the mass ratio of DHA to phospholipids (i.e., sphingomyelin and / or lecithin) is 0.5-13:1, and the mass ratio of ARA to phospholipids is 0.5-17:1.

[0008] According to a specific embodiment of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is 0.2-5:1.

[0009] According to a specific embodiment of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is 0.3-3:1.

[0010] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0011] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0012] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0013] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to phospholipids is 0.5-8:1, for example 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1 or 8:1.

[0014] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of ARA to phospholipids is 0.5-10:1, for example 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1.

[0015] According to a specific embodiment of the present invention, in the composition of the present invention, when the phospholipids are sphingomyelin and phosphatidylcholine, the amount of the phospholipids is the total amount of sphingomyelin and phosphatidylcholine, wherein sphingomyelin and phosphatidylcholine can be combined in any proportion.

[0016] According to some specific embodiments of the present invention, in the composition of the present invention, the phospholipid is sphingomyelin.

[0017] According to some specific embodiments of the present invention, in the composition of the present invention, the sphingomyelin is milk phospholipids.

[0018] According to some specific embodiments of the present invention, the composition comprises DHA, ARA and milk lecithin.

[0019] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the DHA can be a commercially available DHA raw material with a higher purity, or it can be a DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutritional regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichthys and Crypthecodinium. Unless otherwise specified, the ratio of the DHA to other functional components in the composition of the present invention is based on the content of DHA in the raw material.

[0020] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the ARA can be a commercially available ARA raw material with higher purity, or can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the composition of the present invention is based on the content of ARA in the raw material.

[0021] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the sphingomyelin can be a commercially available sphingomyelin raw material with higher purity. Unless otherwise specified, the ratio of the sphingomyelin to other functional components in the composition of the present invention is based on the content of sphingomyelin in the raw material. When the sphingomyelin in the composition of the present invention is milk phospholipids, the ratio thereof to other functional components is based on the content of milk phospholipids in the raw material.

[0022] In another aspect, the present invention further provides a food, which contains the above composition of the present invention.

[0023] According to a specific embodiment of the present invention, the food of the present invention can be a common food or a functional food. More specifically, the food is a snack, a nutritional supplement, a health food or a special medical formula food; the present invention does not make special requirements on the specific form of the food, for example, the snack food can be a milk tablet, candy, etc., and the nutritional supplement, dietary supplement health food or special medical formula food can be in the form of oral liquid, powder, capsule, etc.

[0024] According to a specific embodiment of the present invention, the food of the present invention is a dairy product, such as infant formula, milk powder, milk tablets, cheese, liquid dairy products, complementary foods or nutritional supplements. The food of the present invention is not limited to food for infants or children, but can also be food for adults or middle-aged and elderly people.

[0025] According to a specific embodiment of the present invention, in the food of the present invention, the amount of sphingomyelin contained in the food is 20-138 mg / 100 g of food dry matter, calculated based on the amount of sphingomyelin in the composition.

[0026] According to a specific embodiment of the present invention, the content of DHA and ARA in the food of the present invention can be determined according to the ratio with sphingomyelin.

[0027] According to a specific embodiment of the present invention, the food of the present invention preferably contains a total amount of DHA and ARA of 100-180 mg / 100 g of food dry matter.

[0028] It is understandable that for different types of food, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0029] On the other hand, the present invention also provides the use of polyunsaturated fatty acids, the composition of the present invention or the food in the preparation of products that help to enhance and / or improve the social behavior of an individual.

[0030] According to a specific embodiment of the present invention, in the application of the polyunsaturated fatty acids of the present invention in the preparation of products that help to enhance and / or improve the social behavior of individuals, the polyunsaturated fatty acids include DHA and / or ARA. According to a specific embodiment of the present invention, in the polyunsaturated fatty acids, the mass ratio of DHA to ARA is 0.2-5:1. According to a specific embodiment of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is 0.3-3:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0031] According to some specific embodiments of the present invention, the efficacy component in the composition is composed of DHA, ARA and milk lecithin, and the ratio of the three can be any of the above ratios of the present invention. The efficacy refers to enhancing and / or improving the social behavior of an individual.

[0032] According to a specific embodiment of the present invention, in the present invention, the enhancing and / or improving the social behavior of an individual includes: enhancing the social willingness and / or social ability of an individual.

[0033] According to a specific embodiment of the present invention, in the present invention, the social ability includes social adaptability (the ability of an individual to respond to and adapt to the social environment and / or social needs around him / her).

[0034] According to a specific embodiment of the present invention, the composition of the present invention or the above-mentioned food is used in the preparation of a product that helps to enhance and / or improve the social behavior of an individual, and the individual is an infant, a toddler or a child.

[0035] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months, the toddler refers to an infant of 1-3 years old, and the child refers to a minor, particularly a child of 0 to 6 years old (under 7 years old).

[0036] According to some specific embodiments of the present invention, in the present invention, the product can be any of the aforementioned foods, or a food obtained by further processing using the aforementioned composition and / or food as raw materials, without adding or with adding other substances.

[0037] According to some specific embodiments of the present invention, in the present invention, the product can be a medicine, and the medicine is used to treat and / or improve the social behavior of an individual, especially to treat and / or improve the low social behavior ability of an individual. In addition to the DHA, ARA, sphingomyelin and / or lecithin, the medicine of the present invention can also include pharmaceutically acceptable excipients, and the excipients include excipients, diluents, fillers and / or absorption enhancers. The medicine can be in different forms according to the needs of the recipient. For example, powders, tablets, granulations, microcapsules and / or liquid preparations, etc.

[0038] In some specific embodiments of the present invention, the experimental results show that by adding PUFAs, the learning and memory ability and social behavior ability of individuals can be affected, which is specifically reflected in the significant increase in learning rate and memory rate, and the approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency, and relative movement cumulative time are all improved. In some specific embodiments of the present invention, under the condition that the total content of PUFAs remains unchanged, the proportion of ARA in PUFAs is increased, and the results show that the learning rate and memory rate of individuals are both reduced; there is no significant change in social behavior indicators. In some specific embodiments of the present invention, under the condition that the total content of PUFAs remains unchanged, the proportion of DHA in PUFAs is increased, and the results show that it will affect the social behavior of individuals, which is specifically manifested in the significant reduction of approach cumulative time, body contact cumulative time and relative movement cumulative time. In some specific embodiments of the present invention, a combination of PUFAs and lecithin (egg SM) is designed, and the results show that the combination of PUFAs and egg SM can also affect the social behavior ability of individuals, which is specifically manifested in the further significant improvement of approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency, and relative movement cumulative time. In some specific embodiments of the present invention, a combination of PUFAs and milk phospholipids (milk SM) was designed. The results showed that the combination of PUFAs and milk SM can affect the social behavior ability of an individual, which is specifically manifested in that the approach frequency, cumulative approach time, body contact frequency, cumulative body contact time, relative movement frequency, and cumulative relative movement time are further significantly improved.

[0039] The polyunsaturated fatty acids, compositions and foods containing the compositions provided by the present invention are helpful to enhance and / or improve the social behavior of individuals, and there is a certain synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1The results of learning rate detection of each experimental group of PUFAs are shown.

[0041] Figure 2 Shows the test results of memory rate of each experimental group of PUFAs.

[0042] Figure 3 The results of the detection of the convergent frequencies of each experimental group of PUFAs are shown.

[0043] Figure 4 The results of the detection of the approaching cumulative time of each experimental group of PUFAs are shown.

[0044] Figure 5 Results showing the body contact frequency of each experimental group of PUFAs.

[0045] Figure 6 The test results showing the cumulative time of physical contact for each experimental group of PUFAs.

[0046] Figure 7 The results of the relative movement frequency test of each experimental group of PUFAs are shown.

[0047] Figure 8 The results of the relative migration accumulation time of each experimental group of PUFAs are shown.

[0048] Fig. 9 The test results showed that PUFAs and SM synergistically affected the approach frequency of individuals.

[0049] Fig.10 The test results showed that PUFAs and SM synergistically affected the individual's approach accumulation time.

[0050] Fig.11 The results showed that PUFAs and SM synergistically affected the frequency of physical contact of individuals.

[0051] Fig.12 The results showed that PUFAs and SM synergistically affected the cumulative duration of physical exposure of individuals.

[0052] Fig.13 Results showing that PUFAs and SM synergistically affect the relative movement frequency of individuals.

[0053] Fig.14 The test results showed that PUFAs and SM synergistically affected the cumulative relative movement time of individuals. DETAILED DESCRIPTION

[0054] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0055] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0056] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0057] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0058] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0059] In each embodiment and experiment, the DHA, ARA and milk SM used are all commercially available food grade raw materials. Unless otherwise specified, the DHA, ARA and milk SM mentioned in the present invention are all calculated based on the effective content of the functional components DHA, ARA and milk SM in the raw materials.

[0060] Experimental study on the efficacy of nutritional composition in improving individual social ability

[0061] 1. Bee species and groups

[0062] One-day-old Italian honey bees (Apis mellifera) were used. On the basis of the feed honey bee diet, the intervention methods of different experimental groups are shown in Table 1.

[0063] Table 1

[0064]

[0065] 2. Basic honey bee cultivation

[0066] 2.1 Diet preparation

[0067] Preparation of routine diet: Weigh 500 g sucrose and 10 g casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0068] Diet of treatment group: treatment reagent was added to the regular diet; the single-fed group was fed with a daily diet of 40 μL sugar water per bee, and the reagent was concentrated to 5 μL sterile sugar water at one time.

[0069] 2.2 Bee picking

[0070] Select honeycombs of appropriate age from the apiary, quickly transport them back to the laboratory, and place them in an incubator at 35°C and 60-80% humidity. Observe the status of the eclosing bees every day from the second day (if they have not ecloded, continue to culture), and gently remove the eclosing bees with tweezers and divide them into disposable transparent culture cups, 30 per cup, and divide them into enough cups according to the experimental needs.

[0071] 2.3 Bee pretreatment

[0072] The fledged bees were taken directly from the apiary, and the intestines were extracted. After adding 100ul PBS to each intestine and grinding, 50% glycerol was added in a 1:1 ratio and stored at -80℃.

[0073] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS, add 10μL of worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0074] 2.4 Handling and feeding

[0075] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure adequate diet. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0076] Note: If the animal is gavage-fed individually, the diet placed in the feeding cup is CV diet, and only different treatment reagents are added to the gavage-fed diet.

[0077] 3. Experimental testing

[0078] Learning and memory test:

[0079] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0080] (2) Bee starvation treatment: Each cup of test bees (no less than 40 bees) was starved for 2 hours in the morning.

[0081] (3) Bee tying: The starved bees are tied to a specific stand.

[0082] (4) PER (beak extension after starvation) reaction test: Use 50% sugar water to test whether the bees have a PER (beak extension after starvation) reaction. If there is a PER reaction, then odor learning can begin; if most of them do not, then continue to starve, and the cumulative starvation should not exceed 3 hours. Bees without a PER reaction are eliminated.

[0083] (5) Let the bees rest: Place the selected bees with PER response in the behavior observation room (outside the test bench) and let them rest for 15 minutes.

[0084] (6) Learning rate test: Place a single bee on the operating table, facing the tester, and let it stand for 10 seconds. At the 11th second, aim a 10 mL empty syringe containing nonanol in front of the bee's antennae and give air at a constant speed for 6 seconds. At the 5th second of giving air, feed the bee with a cotton swab dipped in 50% sugar water. Feed for 2-3 seconds to ensure that the bee eats a small amount of sugar water. Record the bee's beak extension during the learning rate test to determine the bee's learning rate. The learning rate test was carried out in 5 rounds according to the above method, with an interval of 10 minutes between each round.

[0085] (7) Memory rate test: The test starts from the end of the fifth round of learning rate test, and the memory rate test begins 45 minutes later. The test operation is the same as the learning rate test, but each bee is tested twice, once with the odor of nonanol and once with n-hexanal, and the sugar water cotton swab is replaced with a clean cotton swab. The bee's beak extension during the memory rate test is recorded to determine the bee's memory rate for the odor.

[0086] (8) After the memory rate test is completed, the bees are tested for PER response. Bees without PER response are considered invalid experimental bees.

[0087] Social behavior testing:

[0088] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0089] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0090] (3) The open field was allowed to adapt to the experimental table for 15 minutes, and then a video of the open field was filmed from above for 45 minutes.

[0091] (4) The above video was analyzed using the Etho Vision XT 17 animal behavior analysis system to obtain data on the social behavior ability of honey bees.

[0092] 4. Experimental Results

[0093] (1) Results of the learning and memory experiment

[0094] Establish an animal model to simulate the individual development and neurodevelopment of infants and young children, and measure the indicators related to cognitive function. Learning and memory experiments are the most intuitive manifestation of cognitive function. Figure 1 As shown, the memory rate is Figure 2 As shown. The learning rate and memory rate of Example 1 are significantly higher than those of the control example. As the proportion of ARA in PUFAs increases, the learning rate and memory rate of Examples 2 and 3 decrease, but there is no significant difference from the control example. As the proportion of ARA in PUFAs decreases, the learning rate and memory rate of Example 4 are significantly higher than those of the control example, and there is no significant difference from Example 1. The results show that the addition of PUFAs can significantly improve learning and memory abilities, improve intellectual development, and effectively promote the development of the nervous system.

[0095] (2) Results of social behavior experiments

[0096] Social behavior includes social willingness and / or social ability evaluation, more specifically, tendency towards social ability and social ability evaluation. Approach frequency, physical contact frequency, cumulative physical contact time, relative movement frequency, cumulative relative movement time, and cumulative approach time can directly reflect changes in an individual's social behavior ability.

[0097] The results of the effects of PUFAs on social willingness and / or social ability are as follows Figures 2 to 8 As shown. Compared with comparative example 1, the approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency, and relative movement cumulative time of Example 1 all increased; the approach frequency, approach cumulative time, body contact frequency, and relative movement frequency of Example 2 increased relatively; the approach frequency, body contact frequency, and relative movement frequency of Example 3 increased relatively; and the approach frequency of Example 4 showed an increasing trend. The above results show that the addition of PUFAs can improve social willingness and / or social ability.

[0098] The effects of PUFAs and SM on social behavior Figures 9 to 14 As shown. Compared with Comparative Example 1, Example 5 and Example 1, the approach frequency, approach cumulative time, body contact frequency, body contact cumulative time, relative movement frequency, and relative movement cumulative time of Example 6 were significantly increased, indicating that social behavior ability was significantly improved. The above results show that the nutritional composition of PUFAs and milk SM can significantly improve social behavior ability and can synergistically promote individual development and neural development.

[0099] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A nutritional composition, characterized in that The nutritional composition comprises DHA, ARA and phospholipids, wherein the phospholipids are sphingomyelin and / or lecithin, wherein the mass ratio of DHA to phospholipids is 0.5-13:1, and the mass ratio of ARA to phospholipids is 0.5-17:

1.

2. The nutritional composition according to claim 1, characterized in that The mass ratio of DHA to ARA is 0.2-5:

1.

3. The nutritional composition according to claim 1, characterized in that The mass ratio of DHA to ARA is 0.3-3:

1.

4. The nutritional composition according to claim 1, characterized in that The mass ratio of DHA to ARA is 0.5-2.5:

1.

5. The nutritional composition according to claim 1, characterized in that The mass ratio of DHA to phospholipids is 0.5-8:1, and the mass ratio of ARA to phospholipids is 0.5-10:

1.

6. The nutritional composition according to any one of claims 1 to 5, characterized in that The sphingomyelin is milk phospholipid.

7. The nutritional composition according to claim 1, characterized in that The nutritional composition includes DHA, ARA and milk lecithin.

8. A food, characterized in that The food contains the nutritional composition according to any one of claims 1 to 7.

9. The food according to claim 8, characterized in that The food is a snack, a nutritional supplement, a health food or a special medical purpose formula food.

10. The food according to claim 8, characterized in that The food is a dairy product.

11. The food according to claim 8, characterized in that The food is infant formula, milk powder, milk tablets, cheese, liquid dairy products, complementary foods or nutritional supplements.

12. The food according to any one of claims 8 to 11, characterized in that Calculated based on the amount of sphingomyelin in the nutritional composition, the amount of sphingomyelin contained in the food is 20-138 mg / 100 g of food dry matter.

13. The food according to claim 12, characterized in that The total amount of DHA and ARA contained in food is 100-180 mg / 100 g of food dry matter.

14. Use of polyunsaturated fatty acids, the nutritional composition according to any one of claims 1 to 7, or the food according to any one of claims 8 to 13 in the preparation of a product that helps to enhance and / or improve the social behavior of an individual; in, The polyunsaturated fatty acids include DHA and / or ARA.

15. The use according to claim 14, characterized in that: In the polyunsaturated fatty acids, the mass ratio of DHA to ARA is 0.2-5:

1.

16. The use according to claim 14, characterized in that The enhancing and / or improving individual social behavior includes: enhancing the individual's social willingness and / or social ability.

17. The use according to claim 16, characterized in that The social ability includes social interaction ability and / or social adaptability ability.

18. The use according to any one of claims 14 to 17, characterized in that: The individual is an infant, toddler or child.

Images